Skip to Content
  • Review
  • Open Access

17 November 2025

42 Pages

ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?

,
,
,
and
1
Institute of Cell Biophysics, Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Pushchino 142290, Russia
2
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov, Moscow 117997, Russia
3
Institute of Future Biophysics, Moscow Center for Advanced Studies, Moscow 123592, Russia
*
Author to whom correspondence should be addressed.

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a key component of the renin–angiotensin system’s counter-regulatory pathway. ACE2 is a multifunctional protein whose location and form determine its catalytic and non-catalytic functions, including amino acid transport, the creation of structural complexes, adhesion, and involvement in signaling pathways. In addition, ACE2 influences neurotransmitter systems in the brain. As the main receptor for SARS-CoV-2, ACE2 has been the subject of increasing research interest. Although ACE2 levels in the brain are low, brain damage from SARS-CoV-2 increases the risk of neurodegenerative diseases. This review aims to clarify an important issue: does the temporary inactivation of ACE2 by the SARS-CoV-2 spike protein play a role in Alzheimer-like neurodegeneration, meaning that the protein may serve as a biomarker or therapeutic target?

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.